Literature DB >> 10845594

Direct effects of muscarinic agents on the outflow pathways in human eyes.

K A Erickson1, A Schroeder.   

Abstract

PURPOSE: Recent studies demonstrating the presence of muscarinic receptors and contractile-like cells in the trabecular meshwork tissue and/or cell cultures from human eyes suggest the possibility that there may be a direct effect of muscarinic agonists on outflow facility. The present studies were conducted to determine whether muscarinic agonists could change outflow facility in perfused human ocular anterior segments, which lack an intact ciliary muscle.
METHODS: Human eyes were dissected and perfused according to previously described methods. A steady state baseline facility was established for 90 minutes, after which up to four sequential concentrations ranging from 10(-9) to 10(-3) M of pilocarpine, aceclidine, or carbachol were added to the perfusion medium. In other studies, 10(-6) M atropine was perfused alone followed by 10(-7) M carbachol with 10(-6) M atropine, whereas fellow control eyes received carbachol alone. Outflow facility was measured for 60 minutes after each drug addition. The outflow facility measurement in each eye after drug administration was compared with the baseline measurement.
RESULTS: Outflow facility increased from baseline facility in eyes treated with pilocarpine, aceclidine, or carbachol at lower concentrations (10(-9) to 10(-6) M) but remained unchanged at higher concentrations (10(-4) to 10(-2) M). The effects of carbachol at 10(-7) M were completely blocked by atropine.
CONCLUSIONS: Muscarinic agonists increase outflow facility in human eyes by a direct stimulation of the outflow tissues in the absence of an intact ciliary muscle. This effect is biphasic, occurring at concentrations of 10(-6) M and lower with no effect at higher concentrations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10845594

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Intraocular Pressure Reduction by Femtosecond Laser Created Trabecular Channels in Perfused Human Anterior Segments.

Authors:  Eric Mikula; Guy Holland; Samantha Bradford; Reza Khazaeinezhad; Hadi Srass; Carlos Suarez; James V Jester; Tibor Juhasz
Journal:  Transl Vis Sci Technol       Date:  2021-08-02       Impact factor: 3.048

2.  Pupillary Dilation in Research: More than Meets the Eye.

Authors:  Jacob Szpernal; Jane A Bachman Groth; Niamh Wynne; Vesper Williams; Ryan Spellecy; Catherine Thuruthumaly; Joseph Carroll
Journal:  Curr Eye Res       Date:  2022-05-02       Impact factor: 2.555

3.  RGS2-deficient mice exhibit decreased intraocular pressure and increased retinal ganglion cell survival.

Authors:  Miyuki Inoue-Mochita; Toshihiro Inoue; David L Epstein; Kendall J Blumer; Ponugoti V Rao
Journal:  Mol Vis       Date:  2009-03-06       Impact factor: 2.367

4.  Bimatoprost, prostamide activity, and conventional drainage.

Authors:  Zhou Wan; David F Woodward; Clive L Cornell; Hans G Fliri; José L Martos; Simon N Pettit; Jenny W Wang; Alexander B Kharlamb; Larry A Wheeler; Michael E Garst; Kari J Landsverk; Craig S Struble; W Daniel Stamer
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-09       Impact factor: 4.799

5.  Effects of muscarinic agents on chick choroids in intact eyes and eyecups: evidence for a muscarinic mechanism in choroidal thinning.

Authors:  Debora L Nickla; Xiaoying Zhu; Josh Wallman
Journal:  Ophthalmic Physiol Opt       Date:  2013-05       Impact factor: 3.117

6.  Cyclic mechanical stress and trabecular meshwork cell contractility.

Authors:  Renata F Ramos; Grant M Sumida; W Daniel Stamer
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-04-01       Impact factor: 4.799

Review 7.  Potential Role for Combined Subtype-Selective Targeting of M1 and M3 Muscarinic Receptors in Gastrointestinal and Liver Diseases.

Authors:  Mazen Tolaymat; Margaret H Sundel; Madeline Alizadeh; Guofeng Xie; Jean-Pierre Raufman
Journal:  Front Pharmacol       Date:  2021-11-04       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.